the antibody such that it does not include an Fc region or non-Fc region competent for effector function or complement activation function.

16. The antibody of claim 14, wherein the modification is selected from: a point mutation of the Fc region to impair binding to one or more Fc receptors selected from the following positions: 234, 235, 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 297, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438, and 439; a point mutation of the Fc region to impair binding to C1q selected from the following positions: 270, 322, 329, and 321; eliminating some or all of the Fc region, and a point mutation at position 132 of the CH1 domain.

17. The antibody of claim 16, wherein the modification is at least one point mutation of the Fc region to impair binding to one or more Fc receptors selected from 234, 235, 265, 297 and 329.

18. The antibody of claim 17, wherein the modification is at positions 297 or 265 and 297.

19. The antibody of claim 17, wherein the modification is at positions 234, 235 and 329.

20. The antibody of claim 18, wherein the modification is N297G; D265A and N297A or D265A and N297G.

21. The antibody of claim 19, wherein the modification is L234A, L235A, and P329G.

22. The antibody of any one of the preceding claims, wherein the half-life of the antibody is increased by a modification in the FcRn binding domain of the antibody at a position selected from: 252, 254, 256, 434 and 436.

23. The antibody of claim 22, wherein the modification is at positions 252, 254 and 256.

24. The antibody of claim 22, wherein the modification is at positions 434 and 436.

53. The use of claim 50, wherein the antibody coupled to the therapeutic compound is to be administered at a therapeutic dose.

54. The use of claim 53, wherein the therapeutic dose is TfR-saturating.

55. The use of claim 50, wherein administration of the antibody is at a dose and/or dose frequency calibrated to minimize acute clinical symptoms of the antibody administration.

56. The antibody for use according to claim 45, wherein the BBB is in a human subject.

57. The antibody for use according to claim 56, wherein the dose amount and/or frequency of administration is modulated to reduce the concentration of antibody to which the red blood cells are exposed.

58. The antibody for use according to claim 56, further comprising the step of monitoring the subject for depletion of red blood cells.

59. The antibody for use according to claim 56, wherein the antibody is to be administered at a therapeutic dose.

60. The antibody for use according to claim 59, wherein the therapeutic dose is TfR-saturating.

61. The antibody for use according to claim 56, wherein administration of the antibody is at a dose and/or dose frequency calibrated to minimize acute clinical symptoms of the antibody administration.